← Patent-cliff monitor small molecule WEGOVY SEMAGLUTIDE
Loss of exclusivity February 2039 latest FDA-listed patent expiry
Company NOVO NORDISK INC
Drug detail Brand name WEGOVY Active ingredient SEMAGLUTIDE Strength 25MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval December 2025 Marketing status RX
Listed patents Patent Expires Type 11833248 February 2039 product 12396953 February 2039 product 12239739 May 2034 use U-4388 10278923 May 2034 use U-4389 11033499 June 2033 product 9278123 December 2031 product 11382957 December 2031 product 8129343 December 2031 substance, product 8536122 March 2026 substance, product
Regulatory exclusivity Code Expires NP December 2028 I-935 March 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.